Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales ...

Morgan Stanley believes that Johnson and Johnson has stronger earnings potential driven by its robust product cycle. The bank ...

Johnson & Johnson received approval from the Food and Drug Administration for a treatment for certain patients with multiple myeloma, an incurable form of blood cancer.

Johnson & Johnson (JNJ) is expected to announce a 21% jump in its fourth quarter earnings on January 21, before the bell.

Johnson & Johnson is set to report its Q4 results on Wednesday, facing one of the most important transitions in its modern ...

A Los Angeles jury awarded $40 million on Friday to two women who claimed that talcum powder made by Johnson & Johnson caused their ovarian cancer. The giant health care company said it would appeal ...

The healthcare giant just took a major step that could reshape its MedTech business and boost its dividend track record.

A California jury on Friday awarded $40 million to two women who said Johnson & Johnson‘s baby powder was to blame for their ovarian cancer. Erik Haas, Johnson & Johnson‘s worldwide vice president of ...

By Jonathan Stempel Jan 12 (Reuters) - Johnson & Johnson convinced Delaware's highest court to throw out part of a $1 billion damages award for breaching its 2019 agreement to buy Auris Health, a ...

Q4 2025 earnings call highlights: 2026 guidance to $100B sales, EPS outlook, key drug growth and risks—read the insights now.

A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the ...